Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Profile Name | JAK2 dec exp |
| Gene Variant Detail | |
| Relevant Treatment Approaches |
| Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|---|
| JAK2 dec exp | melanoma | predicted - sensitive | VSV-delta51 | Preclinical - Cell culture | Actionable | In a preclinical study, siRNA knockdown of JAK2 in a melanoma cell line resulted in increased sensitivity to treatment with an oncolytic virus, VSV-delta51, in culture (PMID: 33593882). | 33593882 |